Aurobindo Pharma arm gets US FDA nod for posaconazole injection; share up 1.6%
The product is anticipated to be launched in December 2023, the approved product is estimated to target a market size of $25.4 million.
aurobindo pharma us fda
December 2023
From ₹397 to ₹1,081: This largecap pharma stock surges 170% in 10 months
The homegrown pharma company has outperformed the BSE Sensex and Healthcare index in terms of returns in the last one year.
